Evidence map›Paper›PMID 40542160›Full record

ArticleJournal of gastroenterology2025

Pretreatment serum angiopoietin-2 predicts prognosis and liver functional reserve after successful HCV eradication with sofosbuvir and velpatasvir in patients with HCV-related decompensated cirrhosis.

Naoki Kawagishi, Goki Suda, Yuki Tahata, Hayato Hikita, Takahiro Kodama, Satoshi Mochida, Nobuyuki Enomoto, Seiichi Mawatari, Hidekatsu Kuroda, Daiki Miki and 22 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Naoki Kawagishi *Department of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan.
Goki Suda *Department of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan. gsudgast@pop.med.hokudai.ac.jp.ORCID 0000-0003-0098-9106
Yuki TahataDepartment of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Hayato HikitaDepartment of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Takahiro KodamaDepartment of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Satoshi MochidaDepartment of Gastroenterology and Hepatology, Saitama Medical University, Saitama, Japan.
Nobuyuki EnomotoFirst Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan.
Seiichi MawatariDigestive and Lifestyle Diseases, Department of Human and Environmental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
Hidekatsu KurodaDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University, Iwate, Japan.
Daiki MikiDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Masayuki KurosakiDepartment of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.
Yoichi HiasaDepartment of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan.
Norifumi KawadaDepartment of Hepatology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Taro YamashitaDepartment of Gastroenterology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.
Hiroshi YatsuhashiClinical Research Center, National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan.
Hitoshi YoshijiDepartment of Gastroenterology, Nara Medical University, Nara, Japan.
Naoya KatoDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Taro TakamiDepartment of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Yamaguchi, Ube, Japan.
Hisamitsu MiyaakiDepartment of Gastroenterology and Hepatology, Nagasaki University of Graduate School of Biomedical Sciences, Nagasaki, Japan.
Kentaro MatsuuraDepartment of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Yasuhiro AsahinaDepartment of Gastroenterology and Hepatology, Institute of Science Tokyo, Tokyo, Japan.
Yoshito ItohDepartment of Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Ryosuke TateishiDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Yasunari NakamotoSecond Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Eiji KakazuThe Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Chiba, Japan.
Shuji TeraiDivision of Gastroenterology and Hepatology, Graduate School of Medicine and Dental Sciences, Niigata University, Niigata, Japan.
Masahito ShimizuDepartment of Gastroenterology/internal medicine, Gifu University Graduate School of Medicine, Gifu, Japan.
Yoshiyuki UenoDepartment of Gastroenterology, Faculty of Medicine, Yamagata University, Yamagata, Japan.
Norio AkutaDepartment of Hepatology, Toranomon Hospital, Tokyo, Japan.
Masatsugu OharaDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan.
Naoya SakamotoDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan.
Tetsuo TakeharaDepartment of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.

Funding

Japan Agency for Medical Research and Development JP24fk0210113Japan Agency for Medical Research and Development JP25fk0210174
6 · The paper itself

Abstract

backgroundDirect-acting-antivirals (DAAs) achieve high sustained-virologic response (SVR) rates, even in patients with hepatitis C virus (HCV)-related decompensated liver cirrhosis (LC). However, predictors of post-treatment liver function improvement and survival remain unclear. This study evaluated pretreatment angiopoietin-2 (Ang2) levels as a predictor of prognosis and liver functional reserve after DAA treatment.

methodsThis multicenter retrospective study included 123 patients with HCV-related decompensated LC treated with sofosbuvir/velpatasvir. Serum Ang2 levels were quantified, and liver function was assessed using the Child-Pugh grading at baseline and 12 weeks after the end of treatment (SVR12). Factors associated with prognosis and post-SVR liver functional reserve (Child-Pugh grade C) were investigated.

resultsMultivariate Cox regression analysis revealed that, in addition to age and creatinine levels at SVR12, baseline Ang2 levels (hazard ratio [HR] = 1.151 per 1000 pg/mL, P = 0.033) and Child-Pugh grade C at SVR12 (HR = 11.765, P < 0.001), but not baseline Child-Pugh grade C, were significantly associated with the overall survival. Multivariate analysis revealed that baseline Ang2 levels and baseline Child-Pugh grade C were significantly and independently associated with Child-Pugh grade C at SVR12. The combination of elevated baseline Ang2 levels (≥ 8684 pg/mL; 1 point) and baseline Child-Pugh grade C (1 point) effectively stratified patients with a high likelihood of having Child-Pugh Grade C at SVR12. The incidence rates were as follows: 0 points, 2.1% (2/96); 1 point, 37.5% (9/24); and 2 points, 100% (2/2) (P < 0.001).

conclusionsPretreatment Ang2 levels predict survival and liver functional reserve after SVR in HCV-related decompensated LC.

Indexed as

Angiopoietin-2Antiviral AgentsCarbamatesHepatitis C, ChronicHeterocyclic Compounds, 4 or More RingsLiver CirrhosisSofosbuvirAdultAgedBenzimidazolesBenzopyransBiomarkersFemaleHumansMaleMiddle AgedAngiopoietin-2ANGPT2 protein, humanAntiviral AgentsBenzimidazolesBenzopyransBiomarkersCarbamatesHeterocyclic Compounds, 4 or More RingsSofosbuvirvelpatasvirAngiopoietin-2Decompensated liver cirrhosisHepatitis C virusSofosbuvirVelpatasvir

Identifiers

PMID40542160

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.